The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (DEFINE)
The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a Prospective Open Label Phase I/II Trial
Sponsor: Crolll Gmbh
Listed as NCT01278056, this PHASE1/PHASE2 trial focuses on Increased Iron Storage / Disturbed Distribution and Non-alcoholic Steatohepatitis and remains completed. Sponsored by Crolll Gmbh, it has been updated 5 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Mar 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Crolll Gmbh
- Estimate, GmbH
- University of Magdeburg
For direct contact, visit the study record on ClinicalTrials.gov .